Hjem › Melanom › Minnesota › Rochester
Melanom kliniske forsøg i Rochester, MN
16 studier for Melanom søger deltagere på steder i og omkring Rochester (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekruttererFase 2
- Mayo Clinic in Rochester, Rochester
Pan-tumor MRD Study
RekruttererObservationsstudie
- Mayo Clinic, Rochester
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RekruttererFase 2
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruttererObservationsstudie
- Mayo Clinic (Rochester), Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RekruttererFase 1
- Mayo Clinic - Rochester, Rochester
Project: Every Child for Younger Patients With Cancer
RekruttererObservationsstudie
- Mayo Clinic in Rochester, Rochester
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
RekruttererObservationsstudie
- Mayo Clinic in Rochester, Rochester
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Rekrutterer
- Mayo Clinic in Rochester, Rochester
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RekruttererObservationsstudie
- Mayo Clinic in Rochester, Rochester
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
RekruttererFase 1/2
- Mayo Clinic Rochester, Rochester
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RekruttererFase 3
- Mayo Clinic - PPDS, Rochester
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekruttererFase 2/3
- Mayo Clinic Rochester, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservationsstudie
- Mayo Clinic, Rochester
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RekruttererFase 3
- Mayo Clinic Minnesota, Rochester
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
RekruttererFase 3
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RekruttererFase 1/2
- Mayo Clinic in Minnesota, Rochester
Melanom forsøg i andre byer
- Houston, TX59 studier
- New York City, NY38 studier
- Los Angeles, CA34 studier
- Nashville, TN33 studier
- Pittsburgh, PA31 studier
- Boston, MA26 studier
- Philadelphia, PA23 studier
- San Francisco, CA22 studier
- Durham, NC21 studier
- Atlanta, GA21 studier
- St. Louis, MO21 studier
- Salt Lake City, UT21 studier
Andre studier i Rochester
- Brystkræft42 studier
- Ikke-småcellet lungecancer37 studier
- Metastatisk cancer31 studier
- Kræft (alle typer)30 studier
- Colorektal kræft29 studier
- Ægstockræft29 studier
- Multipelt myelom24 studier
- Prostatakræft22 studier
- Hjertesvigt22 studier
- Bugspytkirtelkræft22 studier
- Lungecancer20 studier
- Livmoderslimhindekræft20 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.